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Summary 
Background Colorectal cancer screening programmes worldwide have been disrupted during the COVID-19 pandemic. 
We aimed to estimate the impact of hypothetical disruptions to organised faecal immunochemical test-based 
colorectal cancer screening programmes on short-term and long-term colorectal cancer incidence and mortality in 
three countries using microsimulation modelling.
Methods In this modelling study, we used four country-specific colorectal cancer microsimulation models–
Policy1-Bowel (Australia), OncoSim (Canada), and ASCCA and MISCAN-Colon (the Netherlands)—to estimate the 
potential impact of COVID-19-related disruptions to screening on colorectal cancer incidence and mortality in 
Australia, Canada, and the Netherlands annually for the period 2020–24 and cumulatively for the period 2020–50. 
Modelled scenarios varied by duration of disruption (3, 6, and 12 months), decreases in screening participation after 
the period of disruption (0%, 25%, or 50% reduction), and catch-up screening strategies (within 6 months after the 
disruption period or all screening delayed by 6 months).
Findings Without catch-up screening, our analysis predicted that colorectal cancer deaths among individuals aged 
50 years and older, a 3-month disruption would result in 414–902 additional new colorectal cancer diagnoses (relative 
increase 0·1–0·2%) and 324–440 additional deaths (relative increase 0·2–0·3%) in the Netherlands, 1672 additional 
diagnoses (relative increase 0·3%) and 979 additional deaths (relative increase 0·5%) in Australia, and 1671 additional 
diagnoses (relative increase 0·2%) and 799 additional deaths (relative increase 0·3%) in Canada between 2020 and 
2050, compared with undisrupted screening. A 6-month disruption would result in 803–1803 additional diagnoses 
(relative increase 0·2–0·4%) and 678–881 additional deaths (relative increase 0·4–0·6%) in the Netherlands, 
3552 additional diagnoses (relative increase 0·6%) and 1961 additional deaths (relative increase 1·0%) in Australia, 
and 2844 additional diagnoses (relative increase 0·3%) and 1319 additional deaths (relative increase 0·4%) in Canada 
between 2020 and 2050, compared with undisrupted screening. A 12-month disruption would result in 1619–3615 
additional diagnoses (relative increase 0·4–0·9%) and 1360–1762 additional deaths (relative increase 0·8–1·2%) in 
the Netherlands, 7140 additional diagnoses (relative increase 1·2%) and 3968 additional deaths (relative increase 
2·0%) in Australia, and 5212 additional diagnoses (relative increase 0·6%) and 2366 additional deaths (relative 
increase 0·8%) in Canada between 2020 and 2050, compared with undisrupted screening. Providing immediate 
catch-up screening could minimise the impact of the disruption, restricting the relative increase in colorectal cancer 
incidence and deaths between 2020 and 2050 to less than 0·1% in all countries. A post-disruption decrease in 
participation could increase colorectal cancer incidence by 0·2–0·9% and deaths by 0·6–1·6% between 2020 and 
2050, compared with undisrupted screening.
Interpretation Although the projected effect of short-term disruption to colorectal cancer screening is modest, such 
disruption will have a marked impact on colorectal cancer incidence and deaths between 2020 and 2050 attributable 
to missed screening. Thus, it is crucial that, if disrupted, screening programmes ensure participation rates return to 
previously observed rates and provide catch-up screening wherever possible, since this could mitigate the impact on 
colorectal cancer deaths.
Funding Cancer Council New South Wales, Health Canada, and Dutch National Institute for Public Health and 
Environment.
Copyright © 2021 Elsevier Ltd. All rights reserved.
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Introduction 
The COVID-19 pandemic represents a considerable global 
health crisis. As of Jan 29, 2021, COVID-19 has caused 
more than 2 166 000 deaths, and the impact of the 
pandemic will continue to evolve in the coming months 
and years.1 During the crisis, many elective and preventive 
health services have been suspended, including some 
organised colorectal cancer screening programmes. 
Population-level colorectal cancer screening programmes 
typically consist of inviting individuals for primary 
screening using a faecal test sent to their home. Indi-
viduals with positive faecal results are then invited for 
diagnostic colonoscopy done by a trained professional.2 In 
some countries, such primary screening has been paused, 
and the number of diag nostic colonoscopy procedures 
have been minimised or suspended. In the Netherlands 
and Canada, primary screening was disrupted between 
March and May, 2020.3,4 In the Netherlands, colonoscopy 
capacity decreased by around 65% and recovered in 
September3 and colorectal cancer diagnoses among people 
aged 55–75 years (ie, those eligible for screening) were 
lower than expected between March and June, 2020.5 In 
Australia, no disruption to primary screening has occurred 
during the pandemic, but many diagnostic colonoscopy 
follow-up services were affected by constraints on the 
health system, whereby the number of diagnostic 
colonoscopies decreased by 55% between March and 
April, 2020, which was followed by signs of recovery, 
although these procedures were not all associated with the 
organised screening programme.6 No change in screening 
participation could be directly attributed to the COVID-19 
pandemic according to the Australian Institute of Health 
and Welfare.7 Outside of any formal disruption, there 
might have also been changes to participation rates for 
both primary screening and diagnostic follow-up, due to 
behavioural changes (such as perceived risks of seeking 
diagnostic care) and reduced health system capacity. 
Detailed data regarding the extent of these informal 
disruptions is not yet available and might not be for 
some time.
The effectiveness of population-level colorectal cancer 
screening is well established, reducing long-term 
colorectal cancer incidence by up to 24% and colorectal 
cancer mortality by up to 31%.8 Modelling studies have 
indicated that decreases in screening participation or 
longer waiting times between a positive screen and a 
diagnostic follow-up colonoscopy reduce the effectiveness 
of screening.9,10 Delays in diagnostic colonoscopy of up to 
Research in context
Evidence before this study
Colorectal cancer screening programmes worldwide have been 
disrupted due to the COVID-19 pandemic. Screening for 
colorectal cancer is known to reduce long-term colorectal 
cancer incidence and mortality. Any disruption to screening 
would reduce these health benefits. Longer waiting times 
between a primary screening and a diagnostic follow-up 
colonoscopy decrease the effectiveness of screening. A delay of 
up to 12 months in screening or diagnostic follow-up can result 
in a loss in life-years gained from screening of up to 10%. It has 
been estimated that a 6-month delay to predicted usual 
colorectal cancer diagnoses and treatment would result in 
11 excess deaths in the next 5 years in Australia attributable to 
shifts from stage 1 to stage 2 alone. In England, it is estimated 
that 2-week delays in diagnosis for all patients for 12 months 
could lead to up to 1563 additional deaths from colorectal 
cancer, which is corroborated by existing microsimulation 
modelling on the long-term impact of delays to diagnosis and 
warnings from the US National Cancer Institute.
We searched PubMed and MEDLINE to identify modelling 
studies about disruption in colorectal cancer screening. 
Our search yielded five studies, but none included a 
comparative modelling study between different countries or 
modelled catch-up scenarios.
Added value of this study
This comparative modelling study using four well calibrated 
and validated models (MIcrosimulation SCreening ANalysis for 
colorectal cancer, Adenoma and Serrated pathway to Colorectal 
CAncer, Policy1-Bowel, and OncoSim) provided a unique 
opportunity to predict short-term and long-term health and 
resource impacts of disruptions to colorectal cancer screening 
caused by the COVID-19 pandemic. By considering a range of 
hypothetical possibilities for the effect of COVID-19 on 
screening, we generated representative results that illustrate 
the scale and scope of both disruption to screening, and the 
effect of measures to mitigate the health impact. Our findings 
indicated excess colorectal cancer cases (specified by stage), 
colorectal cancer deaths, and resource use (ie, number of 
individuals invited, participating, and participating in 
diagnostic follow-up) occurring annually between 2020 and 
2024 and cumulatively between 2020 and 2050 due to 
disruptions to screening caused by the COVID-19 pandemic.
Implications of all the available evidence
The results indicate that disruption to screening programmes 
will have a substantial effect on the absolute number of 
colorectal cancer deaths between 2020 and 2050. Without 
catch-up screening, a 6-month disruption would result in 
678–881 additional deaths in the Netherlands, 1961 in Australia, 
and 1319 in Canada. However, with immediate catch-up 
screening, the impact of such disruption would be minimised to 
a relative increase in excess deaths of 0·1% in all countries. Where 
screening programmes have been disrupted, it is crucial that 
participation rates return to observed rates as soon as possible 
and, if possible, strategies to catch-up screening, to mitigate the 
impact of any disruption.
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12 months can result in a loss in screening benefits (ie, 
life-years gained) of up to 10%,11 and modelling of cancer 
stage shifting at treatment initiation has already been 
applied to delays in diagnosis attributable to COVID-19.12 
However, these studies did not assess the effect of 
disruptions to primary screening, and although data 
regarding the short-term impact of colorectal cancer 
screening disruptions have started to become available,13 
the long-term impact of these disruptions will not be 
apparent for years or decades since precancerous lesions 
that would otherwise be removed at routine screening 
might instead develop into colorectal cancer in later life. 
Additionally, any impact will be difficult to measure 
because of confounding factors, existing trends in 
colorectal cancer incidence and survival, and the absence 
of any meaningful comparator for worldwide disruption 
to such services.
Recognising the need for long-term evidence to inform 
public health decision making, and the potential for 
models to provide this evidence, the COVID-19 and Cancer 
Global Modeling Consortium (CCGMC) was established 
to support decision making in cancer control both during 
and after the COVID-19 crisis. Modelling provides a 
unique opportunity to predict short-term and long-term 
health and resource impacts of disruptions to screening. 
Additionally, modelling enables comparison between 
hypothetical scenarios to assist health-care providers and 
policy makers in timely recovery planning when complete 
real-world data is not yet available.
The aim of this study was to model and assess the 
short-term and long-term impact of the disruption to 
colorectal cancer screening due to the COVID-19 
pandemic in the Netherlands, Australia, and Canada, 
to illustrate the scale and scope of disruptions to 
screening, and the effect of measures to mitigate the 




We used four microsimulation models from different 
institutions participating in the CCGMC to simulate 
colorectal cancer development and the national colorectal 
cancer screening programmes in the Netherlands, 
Australia, and Canada. These countries have similar 
burdens of disease and use faecal immunochemical test 
(FIT)-based national colorectal cancer screening pro-
grammes. A number of hypothetical disruption scenarios 
were simulated to reflect the impact of a range of potential 
disruptions to screening due to the COVID-19 pandemic. 
Table 1 provides an overview of each model and simulated 
national screening programme, and further details on the 
national screening programmes, model assumptions, 
and characteristics are provided in the appendix (pp 2–4).
This comparative modelling analysis was done using 
four country-specific colorectal cancer microsimulation 
models: MIcrosimulation SCreening ANalysis for 
colorectal cancer (MISCAN-Colon; the Netherlands), 
Adenoma and Serrated pathway to Colorectal CAncer 
(ASCCA; the Netherlands), Policy1-Bowel (Australia), and 
OncoSim (Canada). The models’ structure, under lying 
assumptions, calibration, and validation have been 
described elsewhere.10,19–22 Colorectal cancer incidence and 
mortality data used for the models were obtained from the 
Netherlands Cancer Registry, the Australian Institute of 
Health and Welfare Cancer Registry, and the Canadian 
Cancer Registry. Prevalence data were based on autopsy 
studies, which have been described previously.10,19–22
All models simulate the natural history of colorectal 
cancer. MISCAN-Colon and OncoSim assume all 
See Online for appendix
For more on the CCGMC see 
https://ccgmc.org
Netherlands Australia* Canada†
Population size 17·3 million14 25·4 million14 37·6 million14 
COVID-19 incidence (per 100 000 people)‡ 1058·0 107·1 484·4
COVID-19 mortality (per 100 000 people)‡ 38·4 3·5 25·5
Age-standardised colorectal cancer incidence (per 100 000 people)§ 41·0 33·1 31·2
Age-standardised colorectal cancer mortality (per 100 000 people)§ 13·5 8·9 9·9
2020 screening cohort size 2 260 000 1 320 000 2 020 000
Screening test (cutoff value¶) Biennial FIT (47 µg/g) Biennial two-sample FIT 
(20 µg/g)||
Biennial FIT (20 µg/g)
Screening age, years 55–75 50–74 50–74
Screening participation rate 73%15 41%16 41%17
Models MISCAN-Colon, ASCCA Policy1-Bowel OncoSim
FIT=faecal immunochemical test. MISCAN-Colon=MIcrosimulation SCreening ANalysis for colorectal cancer. ASCCA=Adenoma and Serrated pathway to Colorectal CAncer. 
*Included data were obtained from the National Bowel Cancer Screening Program of Australia;16 a high proportion of screening is known to occur outside of national 
programmes in Australia, but this screening cannot be quantified. †OncoSim models the most common screening practice of Canada; across Canada, screening varies by the 
number of samples used for FIT, FIT cutoff values, and screening frequency used. ‡According to the WHO coronavirus disease (COVID-19) dashboard as of Oct 14, 2020.1 
§According to the 2020 WHO world standardised population.18 ¶Tests with a lower threshold are more sensitive for the detection of advanced adenomas and cancer, but also 
have higher false-positive rates. ||In Australia, individuals are invited to complete a two-sample FIT, with a positive result on either test sufficient for diagnostic follow-up, 
whereas in the Netherlands and Canada, a one-sample FIT is offered.
Table 1: COVID-19 and colorectal cancer burden, screening programmes, and modelling characteristics for the Netherlands, Australia, and Canada
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colorectal cancers develop from conventional adenomas 
via the adenoma-carcinoma pathway (figure 1), whereas 
ASCCA and Policy1-Bowel assume that 85% of colorectal 
cancers develop from conventional adenomas and 15% 
develop from serrated lesions. Simulated individuals start 
their modelled lifetime free of disease, and over time 
might develop one or more adenomas or serrated lesions. 
These lesions might grow and transition into preclinical 
colorectal cancer. A preclinical colorectal cancer might 
become symptomatic, leading to clinical detection. An 
individual with colorectal cancer has a probability of 
dying from the colorectal cancer. This probability is 
calibrated to local colorectal cancer survival data and 
dependent on the stage of the colorectal cancer and 
whether colorectal cancer was detected through screening 
or clinically (outside of screening). Each model includes a 
screening component to simulate the local screening 
programme, including primary FIT-based screening and 
diagnostic colonoscopy follow-up. This component will 
lead to some cancers being prevented completely by the 
detection and removal of adenomas, and other cancers 
detected at earlier stages with more favourable survival. 
The models also tracked the following outcomes: false-
positive FIT test results, complications associated with 
colonoscopy, increased detection of precursor lesions that 
would not have progressed to cancer, and false-negative 
Figure 1: Natural history of colorectal cancer simulated by MISCAN-Colon, ASCCA, Policy1-Bowel, and OncoSim models
MISCAN-Colon and OncoSim only simulate the adenoma-carcinoma pathway, whereas ASCCA and Policy1-Bowel models include both the adenoma-carcinoma 
pathway and the serrated pathway. *ASCCA and Policy1-Bowel additionally assume that small and medium adenomas with high-grade dysplasia or villous structure 
and serrated sessile adenomas can progress to preclinical colorectal cancer.












Small serrated sessile adenoma
(<10 mm)*
Large serrated sessile adenoma
(≥10 mm)
Small hyperplastic polyp (<10 mm) Large hyperplastic polyp (≥10 mm)
Disruption period Catch-up screening Participation with primary 
screening during recovery period
Participation with diagnostic 
follow-up during recovery period
Comparator NA NA No changes No changes
Base case 6-month disruption to screening 
(April–September, 2020, inclusive)
None No changes No changes
Duration of disruption
3 months 3-month disruption to screening 
(April–June, 2020, inclusive)
None No changes No changes
12 months 12-month disruption to screening 
(April, 2020–March, 2021 inclusive)
None No changes No changes
Reduced participation during recovery period
Participation reduced by 
50% in first 3 months, and by 
25% in second 3 months
6-month disruption to screening 
(April–September, 2020, inclusive)
No catch-up screening Participation reduced by 50% in the 
first 3 months and by 25% in the 
second 3 months
Participation reduced by 50% in the 
first 3 months and by 25% in the 
second 3 months
Participation reduced by 50% 
for 6 months 
6-month disruption to screening 
(April–September, 2020, inclusive)
No catch-up screening Participation reduced by 50% for 
6 months
Participation reduced by 50% for 
6 months
Inclusion of catch-up screening
Immediate catch-up 6-month disruption to screening 
(April–September, 2020, inclusive)
Catch-up screening at usual participation 
rates for 6 months after the disruption
No changes No changes
Delayed catch-up 6-month disruption to screening 
(April–September, 2020, inclusive)
All screening is delayed by 6 months, 
including for people not affected by the 
disruption; new cohorts invited for 
screening at usual time
No changes No changes
NA=not applicable.
Table 2: Disruption scenarios
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test results. Further assumptions on test characteristics, 
risk of colonoscopy complications, and screening 
participation, including screening uptake and adherence, 
are listed in the appendix (pp 2–4).
Modelled scenarios 
Each scenario consists of two periods: a disruption period 
and a recovery period. During the disruption period, we 





















reduced by 50% in 
first 3 months and 
25% in second 







reduced by 50%), 
and no catch-up 
screening
6-month disruption, 









Change in number of colorectal cancer diagnoses
2020 12 512 –1558 (–12·5%) –759 (–6·1%) –2412 (–19·3%) –2198 (–17·6%) –2198 (–17·6%) –626 (–5·0%) –1408 (–11·3%)
2021 12 970 363 (2·8%) 183 (1·4%) –166 (–1·3%) 194 (1·5%) –31 (–0·2%) 895 (6·9%) 555 (4·3%)
2022 12 977 737 (5·7%) 363 (2·8%) 1312 (10·1%) 1178 (9·1%) 850 (9·4%) –125 (–1·0%) 1620 (12·5%)
2023 13 400 102 (0·8%) 43 (0·3%) 495 (3·7%) 310 (2·3%) 433 (3·2%) –50 (–0·4%) –287 (–2·1%)
2024 13 526 323 (2·4%) 153 (1·1%) 547 (4·0%) 462 (3·4%) 481 (3·6%) –25 (–0·2%) –104 (–0·4%)
2020–50 451 697 803 (0·2%) 414 (0·1%) 1619 (0·4%) 1147 (0·2%) 1255 (0·3%) –36 (0·0%) –67 (0·0%)
Change in number of colorectal cancer deaths
2020–50 169 016 678 (0·4%) 324 (0·2%) 1360 (0·8%) 975 (0·6%) 609 (0·6%) –7 (0·0%) –52 (0·0%)
ASCCA (Netherlands)
Change in number of colorectal cancer diagnoses
2020 13 562 –1866 (–13·8%) –933 (–6·9%) –2799 (–20·6%) –2559 (–18·9%) –2566 (–18·9%) –932 (–6·9%) –1760 (–13·0%)
2021 13 473 309 (2·3%) 154 (1·1%) –457 (–3·4%) 54 (0·4%) –266 (–2·0%) 1261 (9·4%) 757 (5·6%)
2022 13 146 1104 (8·4%) 552 (4·2%) 1807 (13·7%) 1610 (12·2%) 1657 (12·6%) –131 (–1·0%) 1982 (15·1%)
2023 13 213 125 (0·9%) 63 (0·5%) 739 (5·6%) 416 (3·1%) 606 (4·6%) –19 (–0·1%) –282 (–2·1%)
2024 13 043 451 (3·5%) 226 (1·7%) 737 (5·7%) 627 (4·8%) 640 (4·9%) –37 (–0·3%) –107 (–0·8%)
2020–50 405 025 1803 (0·4%) 902 (0·2%) 3615 (0·9%) 2883 (0·7%) 3091 (0·8%) 74 (0·0%) 267 (0·1%)
Colorectal cancer deaths
2020–50 142 621 881 (0·6%) 440 (0·3%) 1762 (1·2%) 1395 (1·0%) 1500 (1·1%) 38 (0·0%) 131 (0·1%)
Policy1-Bowel (Australia)
Change in number of colorectal cancer diagnoses
2020 17 391 –1537 (–8·8%) –759 (–4·4%) –2264 (–13·0%) –2092 (–12·0%) –2075 (–11·9%) –773 (–4·4%) –1516 (–8·7%)
2021 17 397 313 (1·8%) 176 (1·0%) –286 (–1·6%) 111 (0·6%) –129 (–0·7%) 892 (5·1%) 551 (3·2%)
2022 18 458 492 (2·7%) 243 (1·3%) 548 (3·0%) 767 (4·2%) 816 (4·4%) 20 (0·1%) 534 (2·9%)
2023 18 548 202 (1·1%) 78 (0·4%) 456 (2·5%) 409 (2·2%) 456 (2·5%) 8 (0·0%) 307 (1·7%)
2024 18 618 308 (1·7%) 138 (0·7%) 454 (2·4%) 452 (2·4%) 492 (2·6%) 7 (0·0%) 305 (1·6%)
2020–50 618 564 3552 (0·6%) 1672 (0·3%) 7140 (1·2%) 5365 (0·9%) 5831 (0·9%) 205 (0·0%) 1177 (0·2%)
Change in number of colorectal cancer deaths
2020–50 196 336 1961 (1·0%) 979 (0·5%) 3968 (2·0%) 2897 (1·5%) 3233 (1·6%) 126 (0·1%) 423 (0·2%)
OncoSim (Canada)
Change in number of colorectal cancer diagnoses
2020 21 721 –1417 (–6·5%) –832 (–3·8%) –1737 (–8·0%) –1551 (–7·1%) –1628 (–7·5%) –827 (–3·8%) –1084 (–5·0%)
2021 21 970 406 (1·8%) 302 (1·4%) –238 (–1·1%) 170 (0·8%) –41 (–0·2%) 1169 (5·3%) 622 (2·8%)
2022 22 295 785 (3·5%) 1124 (5·0%) 1080 (4·8%) 923 (4·1%) 1050 (4·7%) –53 (–0·2%) 470 (2·1%)
2023 22 295 762 (3·4%) 1101 (4·9%) 1080 (4·8%) 923 (4·1%) 1050 (4·7%) –53 (–0·2%) 470 (2·1%)
2024 22 295 785 (3·5%) 1124 (5·0%) 1080 (4·8%) 923 (4·1%) 1050 (4·7%) –53 (–0·2%) 493 (2·2%)
2020–50 841 511 2844 (0·3%) 1671 (0·2%) 5212 (0·6%) 3733 (0·4%) 4393 (0·5%) 142 (0·0%) 229 (0·0%)
Change in number of colorectal cancer deaths
2020–50 311 133 1319 (0·4%) 799 (0·3%) 2366 (0·8%) 1707 (0·5%) 2002 (0·6%) 65 (0·0%) –66 (0·0%)
Data are presented as absolute change in individuals aged 50 years and older compared with the comparator scenario of undisrupted screening; numbers in parentheses show percentage change compared with 
the comparator scenario. MISCAN-Colon=MIcrosimulation SCreening ANalysis for colorectal cancer. ASCCA=Adenoma and Serrated pathway to Colorectal CAncer. 
Table 3: Changes in colorectal cancer diagnoses and deaths between 2020 and 2050 relative to undisrupted screening for MISCAN-Colon, ASCCA, Policy1-Bowel, and OncoSim
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paused for 3, 6, or 12 months. The recovery period was 
defined as a 6-month or 12-month period after the 
disruption period. To estimate the impact of screening 
disruptions, we simulated a comparator scenario with 
typical country-specific screening and follow-up partic-
ipation rates for 2020 (ie, no disruption or recovery period) 
based on data obtained from the national screening 
programmes of the Netherlands, Australia, and Canada.15–17
To estimate the effects of different durations of disrup-
tion, and recovery periods (including post-disruption 
participation and catch-up screening), we simulated a 
base case scenario in which a 6-month disruption period 
from April to September, 2020, was assumed, with no 
catch-up screening or changes to participation in the 
recovery period. We designed three groups of scenarios by 
varying the following parameters: length of screening 
disruption (3, 6, or 12 months); decreases in participation 
rates for primary screening and diagnostic follow-up 
during the recovery period following a 6-month disruption 
(0%, 25%, or 50%); and simulation of catch-up scenarios, 
which required an increase in capacity and increased 
workload, whereby both individuals who missed screening 
during the disruption period and individuals scheduled 
for usual screening were invited for screening to reduce 
the backlog caused by the disruption in the 6-month post-
disruption period (yes or no; table 2).
We also simulated six additional scenarios to combine 
different aspects such as the length of screening 
disruption, decreases in participation, and catch-up 
scenarios from the primary scenarios (appendix p 4).
Figure 2: Projected changes in colorectal cancer mortality among individuals aged 50 years and older relative to the comparator scenario according to MISCAN-Colon, ASCCA, Policy1-Bowel 
and OncoSim models
For the base case scenario, a 6-month disruption period from April to September, 2020, was assumed, with no catch-up or changes to participation in the recovery period. The predicted number of 
colorectal cancer deaths in 2020 in the comparator scenario was 4112 according to MISCAN-Colon, 5208 according to ASCCA, 6198 according to Policy1-Bowel, and 8134 according to OncoSim. 
MISCAN-Colon=MIcrosimulation SCreening ANalysis for colorectal cancer. ASCCA=Adenoma and Serrated pathway to Colorectal Cancer.
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Outcomes 
Outcomes for the comparator scenario are reported as 
absolute numbers for individuals aged 50 years and older, 
and the outcomes for each disruption scenario are 
represented as both absolute and relative changes 
compared with the comparator scenario. Relative changes 
were presented as percentage change. The number of indi-
viduals eligible for, and participating in, primary screening 
and the number of colonoscopies done are presented for 
2020 and 2021. Annual colorectal cancer incidence by stage 
were calculated for the period 2020 to 2024. Cumulative 
totals for colorectal cancer incidence by stage, colorectal 
cancer mortality, and life-years lost compared with 
undisrupted screening were calculated for the period 
2020–50. Additionally, age-group specific cumulative totals 
were calculated for colorectal cancer incidence, colorectal 
cancer mortality, and life-years lost for three scenarios with 
6-months disruption: the base case scenario, one scenario 
with 50% reduced participation during the 6-month 
recovery period, and an immediate catch-up scenario.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to the data in the 
study and the final responsibility to submit for publication.
Results
For the comparator scenario (no disruption to services), 
MISCAN-Colon predicted 12 512 colorectal cancer 
Figure 3: Projected changes in colorectal cancer incidence among individuals aged 50 years and older relative to the comparator scenario according to MISCAN-Colon, ASCCA, Policy1-Bowel 
and OncoSim models
For the base case scenario, a 6-month disruption period from April to September, 2020 was assumed, with no catch-up screening or changes to participation in the recovery period. The predicted 
number of colorectal cancer cases in 2020 for the comparator scenario was 12 512 according to MISCAN-Colon, 13 562 according to ASCCA, 17 391 according to Policy1-Bowel, and 21 721 according to 
OncoSim. MISCAN-Colon=MIcrosimulation SCreening ANalysis for colorectal cancer. ASCCA=Adenoma and Serrated pathway to Colorectal Cancer.
A Duration of disruption


















C Inclusion of catch-up screening



























































Participation reduced by 50% in first
 3 months and 25% in second 
3 months
Participation reduced by 50% for
6 months
Year Year Year Year
Articles
8 www.thelancet.com/gastrohep   Published online February 3, 2021   https://doi.org/10.1016/S2468-1253(21)00003-0
diagnoses and 4112 colorectal cancer deaths in 2020 in the 
Netherlands, and 169 016 colorectal cancer deaths between 
2020 and 2050 (table 3; figure 2). ASCCA predicted slightly 
more colorectal cancer diagnoses and deaths in the 
Netherlands, with 13 562 diagnoses and 5208 deaths in 
2020, and 142 621 total colorectal cancer deaths between 
2020 and 2050 (table 3; figure 2). Policy1-Bowel predicted 
17 391 colorectal cancer diagnoses and 6198 colorectal 
cancer deaths in Australia in 2020, and 196 336 colorectal 
cancer deaths between 2020 and 2050 (table 3; figure 2). 
OncoSim predicted 21 721 colorectal cancer diagnoses and 
8134 colorectal cancer deaths in Canada in 2020, and 
311 133 colorectal cancer deaths between 2020 and 2050 
(table 3; figure 2).
With 6-month disruption and no catch-up screening, 
for the Netherlands, MISCAN-Colon and ASCCA 
predicted a decrease in colorectal cancer diagnoses of 
12·5% and 13·8%, respectively, in 2020 (table 3; figure 3). 
Cumulatively for the period 2020–50, MISCAN-Colon 
estimated 803 additional colorectal cancer diagnoses 
(relative increase 0·2% among individuals aged 50 years 
and older between 2020 and 2050) and 678 additional 
deaths (relative increase 0·4%), and ASCCA estimated 
1803 (relative increase 0·4%) additional colorectal cancer 
diagnoses and 881 additional deaths (relative increase 
0·6%) in the Netherlands. For Australia, colorectal 
cancer diagnoses were estimated to decrease in 2020 by 
8·8%, with 3552 additional colorectal cancer diagnoses 
(relative increase 0·6%) and 1961 additional deaths 
(relative increase 1·0%) between 2020 and 2050. In 
Canada, compared with the comparator scenario, a 
relative decrease in colorectal cancer diagnoses of 6·5% 
was predicted to occur in 2020, and 2844 (relative 
increase 0·3%) additional colorectal cancer diagnoses 
and 1319 (relative increase 0·4%) additional deaths were 
estimated for the period 2020–50. The decrease in 
colorectal cancer diagnoses in 2020 was followed by a 
corresponding peak in colorectal cancer incidence in all 
four models in 2022, followed by a sustained increase in 
the number of diagnoses. Age-group specific results for 
these models estimated that the impact of disruptions 
increased with increasing age. In the 50–59 year age 
group, the impact of disruptions to screening services 
on colorectal cancer incidence and mortality was 
estimated to be small (table 4).
Without catch-up screening or any long-term decrease 
in participation, the effect of a disruption on colorectal 
cancer incidence and mortality was proportional to the 
length of the disruption, with a 3-month disruption having 
roughly half the impact of a 6-month disruption, and a 
12-month disruption having roughly twice the impact of a 
6-month disruption (table 3; figures 2 and 3).
A reduction in participation during the recovery period 
increased the impact of the disruption. For scenarios 
with a 6-month disruption followed by a 50% reduction 
in participation during the 6-month recovery period, 
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0·3–0·9% and mortality by 0·6–1·6% in the modelled 
cohorts between 2020 and 2050 (figures 2 and 3).
Offering catch-up screening to individuals who missed 
screening during the disruption period mitigated the 
impact of the disruption: a catch-up screen within 
6 months after the disruption increased the number of 
colorectal cancer diagnoses, matching that for the 
comparator scenario by 2022 for all four models, and 
increased colorectal cancer deaths by less than 0·1% 
between 2020 and 2050 in all countries (figures 2 and 3). 
In the catch-up scenario in which screening was delayed 
by 6 months, the models predicted that annual colorectal 
cancer incidence would return to that of the comparator 
scenario after 6 years in the Netherlands, and after 
approximately 10 years in Australia and Canada. In this 
scenario, the increase in colorectal cancer deaths is 
slightly higher than scenarios in which immediate catch-
up was offered, but the total increase in deaths remained 
less than 0·2% between 2020 and 2050 for all four models. 
Full results, including colorectal cancer incidence by 
stage, are shown in the appendix (pp 5–8).
Additional outcomes such as the number of individuals 
eligible, number of individuals participating, diagnostic 
follow-up colonoscopies, colorectal cancer incidence by 
stage, colorectal cancer deaths, and life-years lost are 
included in the appendix (pp 9–12). For scenarios with 
catch-up screening, additional resource demand was 
predicted for primary FIT screening and diagnostic colono-
scopies, with colonoscopy demand nearly doubling during 
the 6-month recovery period with immediate catch-up 
screening. The additional outcomes also highlight the 
stage shift, with much of the increase in colorectal cancer 
incidence occurring for stage 4 colorectal cancers (up to 
0·8% increase in the Netherlands, 2·8% increase in 
Australia, and 0·5% increase in Canada between 2020 and 
2050 with a 6-month disruption; appendix pp 5–8). This 
shift in incidence to stages with worse survival rates 
explains the corresponding increase in colorectal cancer 
mortality observed. No changes to survival were assumed 
for delays in diagnosis that did not result in a stage shift.
In the additional scenarios modelled, the results for 
different combinations of disruption length, participation 
decrease, and catch-up screening were consistent with the 
results observed in the main scenarios (appendix pp 9–12).
Discussion 
This study predicts that should the COVID-19 pandemic 
disrupt colorectal cancer screening services, the long-
term impact could lead to thousands of additional 
colorectal cancer deaths. Disruptions of up to 12 months 
to colorectal cancer screening services could result in up 
to 3968 excess deaths in Australia, 2366 in Canada, and 
1360–1762 in the Netherlands. Furthermore, reduced 
participation in screening during the post-disruption 
recovery period was estimated to result in hundreds of 
additional deaths. To minimise the long-term impact of 
disruptions in colorectal cancer screening services, it is 
important to catch-up disrupted screening invitations 
either immediately or with a delay, since it is estimated 
that such an approach would reduce the impact to less 
than a 0·2% relative increase in excess colorectal cancer 
deaths compared with undisrupted screening for all 
three countries.
Our findings are consistent with existing studies, which 
demonstrated the importance of ensuring cancer diag-
noses continue during the COVID-19 pandemic. For 
instance, Degeling and colleagues estimated that 3-month 
delays to melanoma, breast, colorectal, and lung cancer 
diagnoses and treatment would result in 90 excess deaths 
over the next 5 years in Australia for patients diagnosed in 
2020, and a 6-month delay would result in 350 excess 
deaths.12 A similar study estimated thousands of excess 
deaths attributable to diagnostic delays in England for 
breast, colorectal, oesophageal, and lung cancer, which is 
consistent with microsimulation modelling on the long-
term impact of delays to diagnosis and warnings from the 
US National Cancer Institute.9,13,23
When restrictions lift and health systems regain 
capacity, governments face unique challenges to ensure a 
safe and effective return to screening. This modelling 
study has presented a clear argument for the health 
benefits of catch-up screening, but in practice admin-
istering modifications to existing population screening 
programmes could prove challenging. Individuals might 
skip screening regardless of whether screening pro-
grammes were paused, due to a real or perceived increased 
risk associated with screening or follow-up colonoscopy, 
and it might prove difficult to ensure these people return 
to screening. When it becomes possible, governments 
must make a concerted effort to ensure individuals have 
both the opportunity and confidence to catch up or resume 
their cancer screening as soon as they can.
The differences observed in the projected impact of 
screening disruptions on health outcomes across the four 
models can be explained by three key differences: colorectal 
cancer incidence, screening programmes (eg, eligibility 
criteria, participation rates, screening test performance), 
and model assumptions. Canada and Australia use the 
same age thresholds for screening eligibility, have similar 
screening participation rates, and use similar FIT cutoff 
values to recall individuals for follow-up colonoscopy; 
however, Australia uses a two-sample FIT test, which is 
much more sensitive than the one-sample FIT test used in 
the Netherlands and most parts of Canada. The Dutch pro-
gramme targets a slightly older population and has a much 
higher screening participation rate than Australia and 
Canada (>70%). Any pause to screening would have a 
greater impact in a population with higher colorectal 
cancer incidence, screening participation rates, and test 
sensitivity, which was observed in this study. ASCCA and 
MISCAN-Colon simulated the Dutch population, and 
their cumulative results are similar but annual results 
differed slightly, as a result of differences in the underlying 
model structure and assumptions–eg, ASCCA simulates 
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both the adenoma-carcinoma and serrated polyp pathways 
whereas MISCAN-Colon assumes non-bleeding adenomas 
that are systematically missed by FIT.24 Such differences in 
modelling assumptions are likely to be present in all 
models used, but are most clearly illustrated by the 
differences in findings identified by the ASCCA and 
MISCAN-Colon models, since they both projected 
estimates for the Netherlands. By using models that were 
developed wholly or in part by independent groups, we 
reduced the risk of systematic bias.
Colonoscopy capacity is a key concern as demand often 
exceeds supply, leading to long waiting times (although 
this demand is not always generated by the screening 
programme).25 Catch-up screening might temporarily 
increase colonoscopy demand to nearly twice that of 
normal levels, which might exceed the capacity of health 
systems. Further studies are required and have been 
planned to assess the viability of targeted catch-up 
screening strategies, such as using higher FIT cutoff 
values at screening during the recovery period to prioritise 
individuals who are at increased risk.
Ongoing monitoring of participation rates during and 
after the pandemic will demonstrate the effect of changing 
patient behaviours on screening levels. Our findings 
suggest that COVID-19 associated decreases in screening 
participation can lead to worse health outcomes. This 
finding is underlined by previous studies that have 
estimated that higher screening participation rates 
markedly increase the health benefits of screening, while 
remaining cost-effective.10 The task of ensuring individuals 
understand the importance of screening and have the 
confidence to return to screening safely is key, especially 
in countries with relatively low participation rates such as 
Canada and Australia. Disseminating findings that 
highlight the benefits of screening such as those included 
in this study is crucial, to enable individuals to make 
informed decisions about balancing cancer screening and 
COVID-19 risk. Previous studies have shown that mass 
media campaigns can improve colorectal cancer screening 
participation, have positive effects on long-term health 
impacts, and are highly cost-effective.23,26 Similar media 
campaigns might be necessary to return participation 
rates to pre-2020 levels. Programmes that require general 
practitioner (GP) attendance for primary screening could 
consider transitioning to a postal-based system similar to 
that currently used in Australia and the Netherlands, to 
reduce the requirement for in-person interaction, alleviate 
strain on GP services, and relieve patient fear regarding 
the possibility of infection.
A key strength of this study is the use of well-established 
microsimulation models. These models have all been 
calibrated and validated using the best available data in 
their settings and have been used to inform local screening 
guidelines.10,19,21,22,27 By modelling the same scenario across 
multiple countries, this study highlights the scale of the 
possible impact of disruptions to screening on long-term 
health outcomes. Although the models varied in the 
absolute number of projected excess deaths due to the 
disruption, all models had similar conclusions. We infer 
from this agreement in modelling results that our 
observations are applicable to a range of settings and 
disruption periods and disruptions are likely to impact the 
efficacy of colorectal cancer screening programmes in 
other high-income countries in a similar way. Future work 
could use these methods and results and estimate 
outcomes for other countries.
This study has several limitations. The reported 
outcomes were model projections and not observed out-
comes, since real-world data on programme disruptions 
are not available at present. Modelling can be completed 
quickly, whereas data for population-level screening pro-
grammes often requires months or years to collect and 
disseminate. We were also not able to incorporate any 
effects attributable to delays to colorectal cancer treat ment, 
which is beyond the scope of the models used and 
appropriate data that could be incorporated into our 
modelling is not yet available to inform any such delay. 
Additionally, the modelled scenarios in this study, 
including effects on participation rates, and the duration of 
these effects, are based on conjecture, and were chosen to 
present a range of possibilities. In particular, any reduction 
in participation is currently modelled as being uniform 
across participants, but in reality changes to participation 
could differ by population factors including socioeconomic 
status, rural or urban location, and sex. It is unlikely that 
any particular scenario is representative of a true disruption 
in any of the settings, but the range of outcomes will 
provide a guide to the expected effect. As real-world data 
on screening disrup tion, changes to diagnostic follow-up, 
and variations in participation rates become available, 
future modelling studies will be required to model such 
data. In this study, the range of the scenarios modelled 
(including the additional disruption scenarios included in 
the appendix) act as a sensitivity analysis for the unknown 
impact of the true disruption. Sensitivity analyses for other 
model param eters, such as colorectal cancer survival, were 
not included in this study, but have been reported for each 
model previously.10,19–22 The comparative analysis with four 
structurally different models across different global 
settings can be considered as a sensitivity analysis on 
biological parameters. All three included countries are 
high-income countries; thus, the projected impact might 
not be generalisable to low-income and middle-income 
countries due to differences in cancer incidence and 
screening accessibility. It was not possible to model any 
less favourable outcomes for patients with colorectal 
cancer attributable to the additional risk of nosocomial 
COVID-19 infections. Such results would allow health 
service providers to balance COVID-19-related health risks 
against the benefits of screening, but this is beyond the 
scope of currently available data and the existing models.
As the COVID-19 pandemic continues, reprioritisation 
of health services globally has led to extraordinary and 
complex challenges. The results of this study clearly 
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demonstrate the impact of screening interruptions on 
colorectal cancer burden, and highlight the importance 
of continuing colorectal cancer screening, either uninter-
rupted or via catch-up screening. Ensuring crucial cancer 
prevention continues where possible without exposing 
patients and medical professionals to unjustifiable 
risks is a difficult task, and one that will continue to 
evolve alongside the pandemic. Where disruptions are 
unavoidable, it is essential that screening is restarted as 
soon as possible afterwards, and catch-up screening is 
held for those that missed screening, to prevent avoidable 
colorectal cancer burden.
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